Načítá se...
Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral Seroreactivity
Existing recombinant adeno-associated virus (rAAV) serotypes for delivering in vivo gene therapy treatments for human liver diseases have not yielded combined high-level human hepatocyte transduction and favorable humoral neutralization properties in diverse patient groups. Yet, these combined prope...
Uloženo v:
Vydáno v: | Mol Ther |
---|---|
Hlavní autoři: | , , , , , , , , , , , , , , , , , , , , |
Médium: | Artigo |
Jazyk: | Inglês |
Vydáno: |
American Society of Gene & Cell Therapy
2018
|
Témata: | |
On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5763027/ https://ncbi.nlm.nih.gov/pubmed/29055620 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ymthe.2017.09.021 |
Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|